Kovcin V, Juranić Z, Babović N, Tomasević Z
Institute of Oncology and Radiology of Serbia, Belgrade.
Srp Arh Celok Lek. 1997 May-Jun;125(5-6):154-6.
Immune complexes are macromolecules consisting of immunoglobulins (antibodies) bound to different antigens [1]. Determination of circulating immune complexes in patients with malignant diseases can be of some interest for prognosis and follow-up of a disease [2, 3]. According to certain data the immune complexes concentration varies in dependence of disease stage [4] and it is not affected by therapy [5]. Precipitation with polyethylenglycol is a physical method for determination of circulating immune complexes, based on the ability of high molecular polymers to precipitate macromolecules from sera [6]. This mechanism of precipitation is not yet well understood, but it is probably based on steric exclusion of water molecules that affects insolubility of immune complex molecules [7]. Repeatedly frozen sera demonstrated rapid decrease in detected concentration of circulating immune complexes [8] by polyethylenglycol. The presence of complement affects solubility of circulating immune complexes [7]. While there are no data about the influence of other proteins in sera or plasma, the aim of this study was to find out if there are any significant differences between the circulating immune complexes levels, determined by polyethylenglycol, in sera, plasma or in only once frozen sera.
Eighteen samples of plasma and sera from patients with malignancy (10 males and 8 females) were examined. Eight of them had non-Hodgkin lymphoma, 4 were with Hodgkin lymphoma, 4 with breast carcinoma and 2 with lung carcinoma. All samples were taken before starting chemotherapy. The circulating immune complexes determination was carried out immediately after the separation of plasma and sera and also in sera frozen for 10 days at -35 degrees C. Circulating immune complexes were determined spectrophotometrically. The absorbance (A450) of serum or plasma in 3.75% of polyethylene glycol, polyethylenglycol (M = 6000) solution was used as the measure of the circulating immune complexes level [9]. The standard for circulating immune complexes determination in g/l was aggregated IgG at 36 degrees C for 30 minutes from the serum of healthy volunteers.
The mean value and the range of circulating immune complexes level (A450) are given in Table 1. The values in g/l are presented in Graph 1. The values of circulating immune complexes in plasma were significantly lower than those in fresh sera (t = 2.8125; p < 0.02). There was no significant statistic difference between levels in circulating immune complexes (A450) in fresh and frozen sera (t = 1.3261; p > 0.1).
In dependence on its concentration polyethylenglycol shows the ability to precipitate proteins selectively [10]. The selectivity was tested mainly towards immunoglobulins and the complement. Results obtained in this study show statistically significant lower circulating immune complexes level in plasma than in serum or frozen serum. The main difference between sera and plasma is in complete absence of fibrinogen, factors V and VIII in sera and in presence of Ca++ ions. Besides that plasma contains an anticoagulant [11]. It is possible that the presence of fibrinogen and some coagulation factors disturb the polyethylenglycol precipitation mechanism. According to this, it might be, that mechanism, based on steric exclusion of water molecules, selectively influences polyethylenglycol precipitation of circulating immune complexes in plasma. It is difficult to say how much Ca++ ion and anticoagulant, as well as the activity of some plasma enzymes, and possible dissociation of circulating immune complexes influence the formation of precipitate. In any case, there is a significant difference between concentration of circulating immune complexes according to substrate. For that reason, it is necessary to detect circulating immune complexes by polyethylanglycol always in the same medium for exact clinical evaluation. (ABSTRACT TRUNCATED)
免疫复合物是由与不同抗原结合的免疫球蛋白(抗体)组成的大分子[1]。测定恶性疾病患者循环免疫复合物对疾病的预后和随访可能具有一定意义[2,3]。根据某些数据,免疫复合物浓度随疾病阶段而变化[4],且不受治疗影响[5]。聚乙二醇沉淀法是一种测定循环免疫复合物的物理方法,基于高分子聚合物从血清中沉淀大分子的能力[6]。这种沉淀机制尚未完全明确,但可能基于影响免疫复合物分子不溶性的水分子空间排斥作用[7]。反复冷冻的血清经聚乙二醇检测显示循环免疫复合物浓度迅速下降[8]。补体的存在会影响循环免疫复合物的溶解度[7]。虽然尚无关于血清或血浆中其他蛋白质影响的相关数据,但本研究的目的是探究经聚乙二醇测定的血清、血浆或仅冷冻一次的血清中循环免疫复合物水平是否存在显著差异。
对18例恶性肿瘤患者(10例男性和8例女性)的血浆和血清样本进行检测。其中8例患有非霍奇金淋巴瘤,4例患有霍奇金淋巴瘤,4例患有乳腺癌,2例患有肺癌。所有样本均在开始化疗前采集。血浆和血清分离后立即进行循环免疫复合物测定,同时对在-35℃冷冻10天的血清进行测定。采用分光光度法测定循环免疫复合物。将血清或血浆在3.75%聚乙二醇(分子量=6000)溶液中的吸光度(A450)作为循环免疫复合物水平的度量[9]。以健康志愿者血清在36℃孵育30分钟的聚集IgG作为循环免疫复合物测定的g/l标准。
表1给出了循环免疫复合物水平(A450)的平均值和范围。图1展示了g/l值。血浆中循环免疫复合物的值显著低于新鲜血清(t = 2.8125;p < 〇〇2)。新鲜血清和冷冻血清中循环免疫复合物水平(A450)无显著统计学差异(t = 1.3261;p > 〇.1)。
聚乙二醇根据其浓度表现出选择性沉淀蛋白质的能力[10]。这种选择性主要针对免疫球蛋白和补体进行了测试。本研究结果显示,血浆中循环免疫复合物水平在统计学上显著低于血清或冷冻血清。血清和血浆的主要区别在于血清中完全不存在纤维蛋白原、V因子和VIII因子以及存在Ca++离子。此外,血浆含有抗凝剂[11]。纤维蛋白原和某些凝血因子的存在可能干扰聚乙二醇沉淀机制。据此,基于水分子空间排斥作用的机制可能选择性地影响血浆中循环免疫复合物的聚乙二醇沉淀。难以说明Ca++离子、抗凝剂以及某些血浆酶的活性以及循环免疫复合物的可能解离对沉淀形成有多大影响。无论如何,根据底物不同,循环免疫复合物浓度存在显著差异。因此,为了进行准确的临床评估,必须始终在相同介质中通过聚乙二醇检测循环免疫复合物。(摘要截断)